Technology is a key component in the development of medical treatments and therapies. Multiple sclerosis (MS) is one disorder that scientists and medical practitioners have been scratching their heads on for a long time. Recent research findings from NIH signals a new wind of hope to the fight against the disorder. The research, as expounded by Dr. Shiva Gopal Vasishta, found out that MS can be thwarted by high-dose immunosuppressive therapy and autologous hematopoietic cell transplant (HDIT/HCT). This treatment procedure involves using a patient’s blood cells to regenerate stem cells.
A Closer Look at the Study
The research took about five years and the research sample involved 24 MS patients of between 26 and 52 years. These patients were suffering from recurring memory loss, brain disorders, and other multiple sclerosis symptoms. They had all been subjected to traditional treatments but had all gone terribly wrong. The treatment procedure proved effective for about 69 percent of the entire sample, with the MS symptoms recurring in only about 31 percent of them.
This impressive HDIT/HCT success rate is unprecedented in the Multiple Sclerosis study. Its effectiveness surpasses the traditionally approved treatment procedures, such as MS drugs. As Dr. Shiva sees it, this new development will potentially become the future of MS treatment. Above that, HDIT/HCT will also offer treatment alternatives to those patients who fail to respond to other forms of treatment.
About Shiva Gopal
Dr. Shiva Gopal Vasishta is a qualified neurologist based in New Jersey. He has practiced in the field for the last four decades and currently practices under the Kennedy University of Hospital. His fluency in both English and Spanish places him at a point higher than other neurologists in New Jersey and beyond.
Vasishta studied at Government Medical College and graduated in 1979 with a BS in neurology. He later improved on his qualifications by undertaking a residency at Boston City Hospital.